drugset / Trial / NCT00609999
Ph I Dasatinib + Erlotinib in Recurrent MG
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary: To determine maximum tolerated dose \& dose limiting toxicity of dasatinib when combined w erlotinib among pts w recurrent MG Secondary: To further evaluate safety \& tolerability of dasatinib + erlotinib To evaluate pharmacokinetics of dasatinib when administered w erlotinib among recurrent MG pts who are on \& not on CYP-3A enzyme inducing anti-epileptic drugs To evaluate for anti-tumor activity with this regimen in this patient population
Timeline
- Start
- 2008-01
- Primary completion
- 2010-07
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Erlotinib | Small molecule | 450 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |